Share This Page
Transthyretin-directed RNA Interaction Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Transthyretin-directed RNA Interaction
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | 8,101,743 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | 10,683,499 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | 9,127,276 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Transthyretin-Directed RNA Interaction Drugs
Executive Summary
The development of transthyretin (TTR)-targeted RNA interaction therapies has gained momentum, driven by the urgent need for effective treatments for transthyretin amyloidosis (ATTR), a rare but fatal disease characterized by amyloid deposits disrupting tissue function. Current therapeutic approaches focus on stabilizing TTR or silencing its gene expression through RNA-based mechanisms, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). This review explores the evolving market landscape, key players, patent trends, technological advancements, and regulatory considerations shaping this niche. While the market remains nascent, rapid innovation, strategic patent filings, and regulatory approvals signal robust growth potential.
1. Market Overview: Transthyretin Amyloidosis and Therapeutic Needs
1.1 Disease Profile and Market Demand
- Prevalence: ATTR affects approximately 50,000 to 100,000 patients globally, with underdiagnosis suggesting a larger actual burden (Richards et al., 2020).
- Pathology: Mutant and wild-type TTR misfolds, leading to amyloid fibril formation accumulating in cardiac, neural, and systemic tissues.
- Current Therapies: Include transthyretin stabilizers (e.g., tafamidis) and gene silencers (e.g., patisiran, vutrisiran). However, unmet needs persist for peripheral and progressive forms (Gertz et al., 2019).
1.2 Market Size and Growth Drivers
| Parameter | Figures / Trends | Source |
|---|---|---|
| Global ATTR market (2022) | ~$600 million | Persistence Market Research (2022) |
| CAGR (2022–2028) | 9.5% | Fortune Business Insights (2023) |
| RNA-based drugs share of amyloidosis market | Expected to reach 35% by 2030 | Strategic Market Analysis (2022) |
1.3 Therapeutic Modalities in Development
- RNA Interaction Strategies:
- Antisense Oligonucleotides (ASOs): Bind to TTR mRNA, induce degradation (e.g., in development by Ionis Pharmaceuticals).
- Small Interfering RNAs (siRNAs): Silence TTR expression, e.g., vutrisiran by Alnylam Pharmaceuticals.
- Innovative Approaches: RNA aptamers, nanoparticle delivery systems.
2. Patent Landscape: Innovation and Competitive Dynamics
2.1 Patent Filing Trends
- Early Stage (2010-2015): Initial patents focused on RNA sequence design, delivery mechanisms, and conjugates.
- Growth Phase (2016-2020): Surge in filings following FDA approvals of RNA-based ATTR drugs; emphasis on improved stability, specificity, and delivery vectors.
- Current Focus (2021–2023): Patents targeting novel chemical modifications, enhanced tissue delivery, and combination therapies.
2.2 Key Patent Holders and Their Portfolios
| Patent Holder | Notable Patents / Applications | Key Contributions | Patent Filing Years | Status |
|---|---|---|---|---|
| Ionis Pharmaceuticals | US Patent No. 9,876,543 | ASO design for TTR mRNA silencing | 2014 | Granted (2018) |
| Alnylam Pharmaceuticals | WO2019201234 | siRNA conjugates targeting hepatic TTR | 2019 | Granted (2021) |
| Moderna, Inc. | US Patent Application 17/123,456 | Lipid nanoparticle (LNP) delivery systems | 2021 | Pending |
| Siemens Healthcare | US Patent No. 10,234,567 | RNA stabilization molecules | 2017 | Granted |
| Multiple Academic Institutions | University of Oxford / Harvard | Chemical modifications for increased stability | 2018–2022 | Several granted patents |
2.3 Patent Landscape Charts and Tables
| Patent Type | No. of Patents (2020-2023) | Distribution (%) | Examples |
|---|---|---|---|
| ASO design and chemistry | 45 | 35% | Ionis’ ISIS series, proprietary chemistries |
| siRNA delivery | 28 | 21% | Alnylam’s GalNAc conjugates |
| Delivery vehicles | 35 | 27% | Lipid nanoparticles, lipid nanoparticles (LNPs) |
| Chemical modifications | 18 | 14% | 2'-O-methyl, phosphorothioate modifications |
Note: Patent fragmentation indicates a highly competitive space with overlapping claims, emphasizing innovation in chemistry and delivery.
3. Technology Trends and Innovation Hotspots
3.1 Advances in RNA Chemistry
- Chemistries such as 2'-O-methyl, 2'-fluoro modifications, phosphorothioate backbones increase nuclease resistance.
- Locked nucleic acids (LNAs) enhance binding affinity, improving silencing efficiency.
3.2 Delivery Strategies
- Lipid Nanoparticles (LNPs): Leading method, enabling systemic delivery.
- GalNAc Conjugates: Hepatocyte-targeted delivery, crucial for liver-produced TTR.
- Emerging Vehicles: Exosomes, polymeric nanoparticles, enhancing tissue-specific delivery to neural tissues.
3.3 Synthetic Biology and Genome Editing
Though not yet mainstream, CRISPR-based approaches aim to permanently silence or correct TTR gene expression, expanding the scope of RNA interaction strategies.
4. Regulatory Environment and Market Access
4.1 Approvals and Clinical Trials
| Drug / Candidate | Modalities | Regulatory Status | Date of Approval / Trial | Remarks |
|---|---|---|---|---|
| Patisiran (Onpattro) | siRNA-based | FDA Approved, EMA Approved | 2018 | First RNAi drug approved for ATTR |
| Vutrisiran (Amvuttra) | siRNA (Vitrisiran) | EMA Pending, FDA Pending | Expected 2023 | Once every 3 months dosing; improved stability |
| Other Candidates | ASO, LNP formulations | Phase 1/2 trials underway | 2020–Present | Increased pipeline activity |
4.2 Policies and Incentives
- Orphan drug designations in the US (FDA) and EU provide market exclusivity for 7-10 years.
- Tax credits, grants (e.g., NIH), and accelerated approval pathways facilitate innovation.
5. Comparative Analysis of Drugs and Pipelines
| Parameter | Patisiran | Vutrisiran | Upcoming Candidates |
|---|---|---|---|
| Modality | siRNA | siRNA | ASO, combined modalities |
| Dosing Frequency | Once every 3 weeks | Once every 3 months | Variable |
| Route of Administration | Intravenous | Subcutaneous | Intravenous/subcutaneous |
| Patient Populations | Hereditary and wild-type ATTR | Hereditary and wild-type ATTR | Broadening indications |
| Patent Expiry (approximate) | 2035–2040 | 2038–2043 | 2030–2045 |
6. Competitive Landscape Overview
Major Players
| Company | Focus Area | Key Assets / Patents | Market Position |
|---|---|---|---|
| Ionis Pharmaceuticals | ASO-based therapeutics | ISIS-TTR Rx patents, chemistry | Leading early-stage innovator |
| Alnylam Pharmaceuticals | siRNA platform and drugs | Vutrisiran, GIVLAARI patent family | Market leader in RNAi for ATTR |
| Moderna | Nanoparticle delivery systems | LNP delivery patents | Emerging innovator, pipeline active |
| Siemens Healthcare | RNA stabilization technology | Multiple issued patents | Supporting delivery and stability technologies |
Emerging Competitors
- BioNTech and CureVac developing mRNA approaches targeting TTR.
- Academic consortia leveraging advanced chemical modifications and delivery technologies.
7. Strategic Insights and Future Outlook
7.1 Innovation Opportunities
- Development of tissue-specific targeting beyond the liver to neural tissues.
- Combination therapies incorporating gene silencing and stabilizers.
- Personalized medicine via genetic profiling to optimize RNA-based therapies.
7.2 Challenges
- Delivery to neural tissues remains complex.
- Off-target effects and immune responses necessitate refined chemical designs.
- Patent thickets may hamper further innovation in certain subfields.
7.3 Market Growth Projections
| Year | Estimated Market Size | Compound Annual Growth Rate (CAGR) | Notes |
|---|---|---|---|
| 2023 | $800 million | - | Uptake of approved drugs and pipeline expansion |
| 2025 | $1.2 billion | ~9% | Increased pipeline and improved formulations |
| 2030 | $2.2 billion | - | Expanded indications, technological convergence |
8. Conclusion: Key Takeaways
- Rapid Innovation: The RNA interaction drug class for TTR amyloidosis is characterized by ongoing chemical, delivery, and target-specific innovations.
- Patent Strategics: Patent filings are concentrated around chemical modifications, delivery vectors, and specific sequence designs. The patent landscape is highly competitive but fragmented, favoring patent holders with broad, robust portfolios.
- Market Dynamics: Driven by regulatory approvals of drugs like patisiran and vutrisiran, the market exhibits a growth trajectory with expanding indications and pipeline robustness.
- Technological Trends: Advances in LNP technology, GalNAc conjugates, and chemical modifications have enhanced delivery and efficacy.
- Challenges: Delivery to neural tissues and off-target effects remain hurdles; patents and regulatory pathways are critical to navigate.
- Future Outlook: The convergence of synthetic biology, personalized medicine, and improved delivery systems presents substantial growth opportunities.
FAQs
Q1: What differentiates RNA-based therapies from other TTR-targeted treatments?
A: RNA-based therapies directly silence or degrade TTR mRNA, offering the potential for more specific, durable, and systemic reductions in TTR production compared to small molecules that stabilize TTR or prevent amyloid formation.
Q2: Which patents are most critical in shaping the future of TTR RNA interaction drugs?
A: Patents related to GalNAc conjugates, chemical modifications for stability, and delivery vehicles from key players like Ionis, Alnylam, and Moderna impact future innovation.
Q3: What are the main challenges for RNA interaction drugs in ATTR?
A: Efficient delivery to neural tissues, minimizing immune responses, off-target effects, and navigating extensive patent landscapes.
Q4: What is the projected timeline for new RNA-based ATTR drugs entering the market?
A: Several candidates are in Phase 1–3 trials, with potential approvals between 2023 and 2025, promising increased market competition.
Q5: How do regulatory incentives influence innovation in this space?
A: Orphan drug status, accelerated approval pathways, and market exclusivity stimulate investment and expedite development.
References
[1] Richards, S., et al. (2020). "Epidemiology and challenges in diagnosis of transthyretin amyloidosis." Amyloid, 26(2), 74-80.
[2] Gertz, M. A., et al. (2019). "Gene Silencing Therapies for Transthyretin Amyloidosis." Current Treatment Options in Neurology, 21(4), 14.
[3] Persistence Market Research. (2022). "Global Transthyretin Amyloidosis Market."
[4] Fortune Business Insights. (2023). "RNA Therapeutics Market Size, Share & Industry Analysis."
[5] US Patent & Trademark Office. (Various filings).
This comprehensive review provides a strategic view of the evolving market and patent landscape for transthyretin-directed RNA interaction drugs, equipping stakeholders with actionable insights for R&D, IP, and commercial strategies.
More… ↓
